Synthesis and biological evaluation of novel indole-pyrimidine hybrids bearing morpholine and thiomorpholine moieties

European Journal of Medicinal Chemistry

Volumn 134, Issue , 2017, Pages 110-118

  Diao, Peng Cheng ^a   Li, Qiu ^a   Hu, Meng Jin ^a   Ma, Yu Feng ^a   You, Wen Wei ^a   Hong, Kwon Ho ^b   Zhao, Pei Liang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antiproliferative activity; Indole pyrimidine; Morpholine; Thiomorpholine; Tubulin polymerization

Indexed keywords

(3 BROMOPHENYL)[3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; (4 BROMOPHENYL)[3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; (4 BROMOPHENYL)[3 (5 NITRO 2 THIOMORPHOLINOPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; (4 CHLOROPHENYL)[6 METHYL 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; (4 METHOXYPHENYL)[3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; (4 METHOXYPHENYL)[3 (5 NITRO 2 THIOMORPHOLINOPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; (4 METHOXYPHENYL)[6 METHYL 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; ANTINEOPLASTIC AGENT; BIPHENYL 4 YL[3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; BIPHENYL 4 YL[6 CHLORO 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; BIPHENYL 4 YL[6 METHYL 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; CYCLOPROPYL[3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]METHANONE; ETHYL 2 (4 METHOXYBENZOYL) 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOLE 1 CARBOXYLATE; ETHYL 2 BENZOYL 6 CHLORO 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOLE 1 CARBOXYLATE; INDOLE DERIVATIVE; INDOLE PYRIMIDINE HYBRID; MORPHOLINE; PYRIMIDINE DERIVATIVE; THIOMORPHOLINE; UNCLASSIFIED DRUG; [(4 BROMOPHENYL)[6 METHYL 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL]]METHANONE; [3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](PHENYL)METHANONE; [3 (5 NITRO 2 THIOMORPHOLINOPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](PHENYL)METHANONE; [6 CHLORO 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](4 CHLOROPHENYL)METHANONE; [6 CHLORO 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](4 METHOXYPHENYL)METHANONE; [6 CHLORO 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](PHENYL)METHANONE; [6 CHLORO 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](THIOPHEN 2 YL)METHANONE; [6 METHYL 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](PHENYL)METHANONE; [6 METHYL 3 (2 MORPHOLINO 5 NITROPYRIMIDIN 4 YLAMINO) 1H INDOL 2 YL](THIOPHEN 2 YL)METHANONE; MORPHOLINE DERIVATIVE; TUBULIN; TUBULIN MODULATOR;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; HCT 116 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; MICROTUBULE ASSEMBLY; MOLECULAR DOCKING; NONHUMAN; ONE POT SYNTHESIS; SUBSTITUTION REACTION; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; METABOLISM; NEOPLASMS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MOLECULAR DOCKING SIMULATION; MORPHOLINES; NEOPLASMS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 85017201451     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2017.04.011     Document Type: Article

References (29)

1. [1] Mora-Bermúdez, F., Huttner, W.B., Novel insights into mammalian embryonic neural stem cell division: focus onmicrotubules. Mol. Biol. Cell. 26 (2015), 4302–4306.
2. [2] Kaur, R., Kaur, G., Gill, R.K., Soni, R., Bariwal, J., Recent developments in tubulin polymerization inhibitors: an overview. Eur. J. Med. Chem. 87 (2014), 89–124.
3. [3] Driowya, M., Leclercq, M.J., Verones, V., Barczyk, A., Lecoeur, M., Renault, N., Flouquet, N., Ghinet, A., Berthelot, P., Lebegue, N., Synthesis of triazoloquinazolinone based compounds as tubulin polymerizationinhibitors and vascular disrupting agents. Eur. J. Med. Chem. 115 (2016), 393–405.
4. [4] Gan-Or, Z., Rouleau, G.A., Benarroch, E.E., Dynamics of microtubules and their associated proteins: recent insights and clinical implications. Neurology, 87, 2016, 2173.
5. [5] Kumar, A.S., Reddy, M.A., Jain, N., Kishor, C., Murthy, T.R., Ramesh, D., Supriya, B., Addlagatta, A., Kalivendi, S.V., Sreedhar, B., Design and synthesis of biaryl aryl stilbenes/ethylenes as antimicrotubule agents. Eur. J. Med. Chem. 60 (2013), 305–324.
6. [6] Strzyz, P., Cytoskeleton: microtubules set the beat. Nat. Rev. Mol. Cell Biol., 17, 2016, 333.
7. [7] Dumontet, C., Jordan, M.A., Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9 (2010), 790–803.
8. [8] Hu, M.J., Zhang, B., Yang, H.K., Liu, Y., Chen, Y.R., Ma, T.Z., Lu, L., You, W.W., Zhao, P.L., Design, synthesis and molecular docking studies of novel indole-pyrimidine hybrids as tubulin polymerization inhibitors. Chem. Biol. Drug Des. 86 (2015), 1491–1500.
9. [9] Pasquier, B., El-Ahmad, Y., Filoche-Rommé, B., Dureuil, C., Fassy, F., Abecassis, P.Y., Mathieu, M., Bertrand, T., Benard, T., Barrière, C., El Batti, S., Letallec, J.P., Sonnefraud, V., Brollo, M., Delbarre, L., Loyau, V., Pilorge, F., Bertin, L., Richepin, P., Arigon, J., Labrosse, J.R., Clément, J., Durand, F., Combet, R., Perraut, P., Leroy, V., Gay, F., Lefrançois, D., Bretin, F., Marquette, J.P., Michot, N., Caron, A., Castell, C., Schio, L., McCort, G., Goulaouic, H., Garcia- Echeverria, C., Ronan, B., Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent andselective inhibitor of Vps34 for the treatment of solid tumors. J. Med. Chem. 58 (2015), 376–400.
10. [10] Peng, W., Tu, Z.C., Long, Z.J., Liu, Q.T., Lu, G., Discovery of 2-(2-aminopyrimidin-5-yl)-4- morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents. Eur. J. Med. Chem. 108 (2016), 644–654.
11. [11] Sutherlin, D.P., Bao, L., Berry, M., Castanedo, G., Chuckowree, I., Dotson, J., Folks, A., Friedman, L., Goldsmith, R., Gunzner, J., Heffron, T., Lesnick, J., Lewis, C., Mathieu, S., Murray, J., Nonomiya, J., Pang, J., Pegg, N., Prior, W.W., Rouge, L., Salphati, L., Sampath, D., Tian, Q., Tsui, V., Wan, N.C., Wang, S., Wei, B., Wiesmann, C., Wu, P., Zhu, B.Y., Olivero, A., Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J. Med. Chem. 54 (2011), 7579–7587.
12. [12] Wallin, J.J., Edgar, K.A., Guan, J.E., Berry, M., Prior, W.W., Lee, L., Lesnick, J.D., Lewis, C., Nonomiya, J., Pang, J.D., Salphati, L., Olivero, A.G., Sutherlin, D.P., O'Brien, C., Spoerke, J.M., Patel, S., Lensun, L., Kassees, R., Ross, L., Lackner, M.R., Sampath, D., Belvin, M., Friedman, L.S., GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther. 10 (2011), 2426–2436.
13. [13] Raynaud, F.I., Eccles, S., Clarke, P.A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., Bjerke, L.M., Kelland, L., Valenti, M., Patterson, L., Gowan, S., de Haven Brandon, A., Hayakawa, M., Kaizawa, H., Koizumi, T., Ohishi, T., Patel, S., Saghir, N., Parker, P., Waterfield, M., Workman, P., Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67 (2007), 5840–5850.
14. [14] Park, S., Chapuis, N., Bardet, V., Tamburini, J., Gallay, N., Willems, L., Knight, Z.A., Shokat, K.M., Azar, N., Viguie, F., Ifrah, N., Dreyfus, F., Mayeux, P., Lacombe, C., Bouscary, D., PI-103, a dual inhibitor of class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22 (2008), 1698–1706.
15. [15] Burger, M.T., Pecchi, S., Wagman, A., Ni, Z.J., Knapp, M., Hendrickson, T., Atallah, G., Pfister, K., Zhang, Y., Bartulis, S., Frazier, K., Ng, S., Smith, A., Verhagen, J., Haznedar, J., Huh, K., Iwanowicz, E., Xin, X., Menezes, D., Merritt, H., Lee, I., Wiesmann, M., Kaufman, S., Crawford, K., Chin, M., Bussiere, D., Shoemaker, K., Zaror, I., Maira, S.M., Voliva, C.F., Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med. Chem. Lett. 2 (2011), 774–779.
16. [16] Rodon, J., Brana, I., Siu, L.L., De Jonge, M.J., Homji, N., Mills, D., Di Tomaso, E., Sarr, C., Trandafir, L., Massacesi, C., Eskens, F., Bendell, J.C., Phase I doseescalation and -expansion study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Invest. New. Drugs 32 (2014), 670–681.
17. [17] Vymětalová, L., Havlíček, L., Šturc, A., Skrášková, Z., Jorda, R., Pospíšil, T., Strnad, M., Kryštof, V., 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)Hpyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases. Eur. J. Med. Chem. 110 (2016), 291–301.
18. [18] G. Castanedo, D.M. Goldstein, R. K. Kondru, M.C. Lucas, W.S. Palmer, S. Price, B. Safina, P.P.A. Savy, E.M. Seward, D.P. Sutherlin. et al., Preparation of Bicyclic Indolylpyrimidine Derivatives for Use as PI3K-p110d Inhibitors and Useful in Treatment of PI3 Kinase Mediated Disorders, WO 2010136491.
19. [19] Rane, R.A., Bangalore, P., Borhade, S.D., Khandare, P.K., Synthesis and evaluation of novel 4-nitropyrrole-based 1,3,4-oxadiazole derivatives as antimicrobial and anti-tubercular agents. Eur. J. Med. Chem. 70 (2013), 49–58.
20. [20] Gregorić, M., Sedić, P.A., Grbčić, K.P.S., Tomljenović, M., Cetina, R., Vianello, S., Raić-Malić. Novel pyrimidine-2,4-dione-1,2,3-triazole and furo[2,3-d]pyrimidine-2-one-1,2,3-triazole hybrids as potential anti-cancer agents: synthesis, computational and X-ray analysis and biological evaluation. Eur. J. Med. Chem. 125 (2016), 1247–1267.
21. [21] Ma, L.Y., Zheng, Y.C., Wang, S.Q., Wang, B., Wang, Z.R., Pang, L.P., Zhang, M., Wang, J.W., Ding, L., Li, J., Wang, C., Hu, B., Liu, Y., Zhang, X.D., Wang, J.J., Wang, Z.J., Zhao, W., Liu, H.M., Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. J. Med. Chem. 58 (2015), 1705–1716.
22. [22] Sribalan, R., Banuppriya, G., Kirubavathi, M., Jayachitra, A., Padmini, V., Multiple biological activities and molecular docking studies of newly synthesized 3-(pyridin-4-yl)-1H-pyrazole-5-carboxamide chalcone hybrids. Bioorg Med. Chem. Lett. 26 (2016), 5624–5630.
23. [23] Bhakta, S., Scalacci, N., Maitra, A., Brown, A.K., Dasugari, S., Evangelopoulos, D., McHugh, T.D., Mortazavi, P.N., Twist, A., Petricci, E., Manetti, F., Castagnolo, D., Design and synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) pyrrole hybrid derivatives: discovery of potent antitubercular agents effective against multidrug-resistant mycobacteria. J. Med. Chem. 59 (2016), 2780–2793.
24. [24] Yang, H.K., You, W.W., Yan, G.H., Jiang, Z.H., Zhao, P.L., Zhou, Z.Z., Efficient one-pot synthesis of 3-amino-7-azaindoles under microwave irradiation. Synth. Commun. 44 (2014), 1165–1171.
25. [25] Zhao, P.L., Ma, W.F., Duan, A.N., Zou, M., Yan, Y.C., You, W.W., Wu, S.G., One-pot synthesis of novel isoindoline-1,3-dione derivatives bearing 1,2,4-triazole moiety and their preliminary biological evaluation. Eur. J. Med. Chem. 54 (2012), 813–822.
26. [26] Ravelli, R.B., Gigant, B., Curmi, P.A., Jourdain, I., Lachkar, S., Sobel, A., Knossow, M., Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428 (2004), 198–202.
27. [27] Shelanski, M.L., Gaskin, F., Cantor, C.R., Microtubule assembly in the absence of added nucleotides. Proc. Natl. Acad. Sci. U.S.A. 70 (1973), 765–768.
28. [28] Barron, D.M., Chatterjee, S.K., Ravindra, R., Roof, R., Baloglu, E., Kingston, D.G.I., Bane, S., A fluorescence-based high-throughput assay for antimicrotubule drugs. Anal. Biochem. 315 (2003), 49–56.
29. [29] Olsson, M.H.M., Søndergard, C.R., Rostkowski, M., Jensen, J.H., PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theor. Comput. 7 (2011), 525–537.